SCHEMBL6538360

SCHEMBL6538360

CC(C)(C)[Si](OCc1cnc2c(NC(=O)c3c(Cl)cccc3Cl)cccc2c1-n1ccnc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CD38 P28907 1/20 0.35
EPHB3 P54753 1/20 0.33
ATR Q13535 1/20 0.33
SLC16A3 O15427 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
ALDH1A1 P00352 2/20 0.32
POLB P06746 1/20 0.32
GHSR Q92847 1/20 0.32
BDKRB2 P30411 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
CRHBP P24387 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6537966 0.85 CYP3A4 (0.45) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6538571 0.85 SLC16A3 (0.38) EPHB3SLC16A3JAK2JAK1TYK2
SCHEMBL6538031 0.84 CYP3A4 (0.44) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6538171 0.84 CYP3A4 (0.50) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6538134 0.83 CYP3A4 (0.43) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6537513 0.83 CYP3A4 (0.46) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6537955 0.83 CYP3A4 (0.46) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6538165 0.83 CYP3A4 (0.43) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6537549 0.82 CYP3A4 (0.39) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6537510 0.81 SLC16A3 (0.37) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0876345-B1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO (JP) 2004-08-18 EP disclosed
US-6008230-A TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-12-28 US disclosed
EP-0876345-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-11-11 EP disclosed
WO-1997014681-A1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-04-24 WO disclosed